Scientists weaponize immune cells to fight Virus-Linked cancer
NCT ID NCT04509726
Summary
This small, early-stage trial tested a new cell therapy for people with advanced or returning nasopharyngeal cancer linked to the Epstein-Barr virus (EBV). Researchers collected and genetically engineered a patient's own immune cells (T cells) to better recognize and attack the virus inside the cancer cells. The main goal was to find the safest and most effective dose of these modified cells to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.